GW Pharmaceuticals (GWP)

Business description

GW Pharmaceuticals is a UK-based speciality pharma company developing cannabinoid medicines. Sativex is marketed by partners in a number of EU countries for MS spasticity. Lead pipeline candidate Epidiolex is entering Phase III for childhood epilepsy.

Share price chart

Share chart

Stock data

Market cap.£1037.2m
Last close438.00p
High / Low (52 weeks)523.5p / 219.2p
Stock market listingLN, US
Forecast net cash (£m)92.4
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual4.72.142.9
Relative *2.1(2)39.7

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Carmat Celldex Therapeutics
Cellectis Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

PEG Ratio (5 yr expected):

Tue, 25 Mar 2014 09:01:13 GMT

Today's Winner And Loser: GW Pharmaceuticals plc Pushes Higher As Circle ...

Fri, 09 Jan 2015 10:30:00 GMT

GW Pharmaceuticals plc Reports First Quarter 2015 Financial Results and ...

Wed, 04 Feb 2015 12:00:00 GMT

Vetr Inc. Downgrades GW Pharmaceuticals PLC- to Hold (GWPH)

Wed, 18 Feb 2015 15:45:00 GMT

GW Pharmaceuticals PLC- Given Consensus Recommendation of “Buy” by ...

Wed, 11 Feb 2015 15:46:10 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2013A 27.3 (8.9) (9.7) (2.6) N/A N/A
2014A 30.0 (17.0) (18.3) (6.4) N/A N/A
2015E 24.7 (42.2) (43.2) (15.2) N/A N/A
2016E 24.1 (41.1) (42.3) (15.1) N/A N/A

Last updated on 24/02/2015

Investment summary

The expansion of GW Pharmaceuticals’ (GW) cannabinoid portfolio beyond Sativex continues to gather momentum. At the forefront is Epidiolex, poised to enter (in Q115) an extensive Phase III clinical programme for refractory childhood epilepsies. With results from one of these studies due by the end of 2015, the clinical development timeline of Epidiolex has accelerated and is ahead of potential competitors. GW's R&D day (Oct 2014) presented encouraging data from the first 58 patients in the FDA-approved expanded access programme for Epidiolex, showing substantial reductions in seizure frequencies with high responder rates, at least comparable to approved anti-epileptic drugs. Cash of £157m at 31 Dec 2014 provides the resources to fund significant investment in manufacturing scale-up and pre-commercialisation activities for the Epidiolex programme in 2015.

Last updated on 02/03/2015

Industry outlook

GW is the leading player in cannabinoid medicines, which have the potential to become novel therapies for a broad range of diseases. Cannabinoids are diverse chemical compounds that GW extracts from different cannabis plant varieties (chemotypes) it has bred.

Last updated on 02/03/2015

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website